Diabetic Nephropathy & Hypertension

Diabetic nephrosis is characterized by cardiovascular disease, progressive proteinuria, glomerulosclerosis, and decline in capillary vessel filtration rate (GFR) resulting in ESRD. Cardiovascular disease within the setting of polygenic disease is outlined as a pulse force per unit area force per unit area mmHg or a pulsation force per unit area force per unit area mmHg. associate elevated urinary simple protein excretion rate, exaggerated force per unit area (BP), and a continuous loss of excretory organ operate are characteristics of DN. Screening for small proteinuria is central to polygenic disease care, and antihypertensive drug agents are used for the first interference and treatment of DN. Angiotensin-converting accelerator inhibitors and angiotnin receptor blockers play central roles and have protecting properties on the far side their BP-lowering effects. BP management in relevancy DN is that the main focus of this review, however tight management of the aldohexose level is equally vital.

  • Hypertension Management
  • Pathogenesis of diabetic nephropathy
  • Hypertension-Clinical and Experimental Models
  • Diabetic Nephropathy–Biomarkers of Disease

Related Conference of Diabetic Nephropathy & Hypertension

August 28-29, 2025

10th World Kidney Congress

London, UK
November 03-04, 2025

29th European Nephrology Conference

Rome, Italy
December 10-11, 2025

12th World Congress on Epidemiology & Public Health

Amsterdam, Netherlands
March 09-10, 2026

17th Nephrology,Renal Medicine & Renal Care

Dubai, UAE
March 26-27, 2026

22nd World Nephrology Conference

Amsterdam, Netherlands
June 29-30, 2026

18th World Nephrology Summit

Aix-en-Provence, France

Diabetic Nephropathy & Hypertension Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in